UroGen Pharma (URGN) Long-Term Deferred Tax (2023 - 2025)

UroGen Pharma (URGN) has reported Long-Term Deferred Tax for 3 consecutive years, with $153.4 million the latest figure, recorded in Q4 2025.

• Quarterly Long-Term Deferred Tax rose 24.73% year-over-year to $153.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $153.4 million (up 24.73% YoY) and the FY2025 annual result came in at $153.4 million, up 24.73% from the prior year.
• Long-Term Deferred Tax climbed to $153.4 million in Q4 2025 per URGN's latest filing, from $122.9 million in the prior quarter.
• Over the last five years, Long-Term Deferred Tax for URGN reached as high as $153.4 million in Q4 2025 and fell as low as $103.6 million in Q4 2023.
• A 3-year average of $126.6 million and a median of $122.9 million in 2024 frame the typical range for Long-Term Deferred Tax.
• Annual changes were most pronounced in 2024 — Long-Term Deferred Tax gained 18.71% — and 2025, when it gained 24.73%.
• Year by year, Long-Term Deferred Tax stood at $103.6 million in 2023, then rose by 18.71% to $122.9 million in 2024, then increased by 24.73% to $153.4 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $153.4 million, $122.9 million, and $103.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.